NCT06015373

The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension

The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension: Insights From Elastography Measurements

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Centro Hospitalar De São João, E.P.E. · Academic / Other
• Sex: All
• Age: 18 Years – 77 Years
• Healthy volunteers: Accepted

Summary

Carvedilol has emerged as the preferred non-selective β-blocker (NSBB) for treating portal hypertension. However, there is still a debate in dosing regimen, specially regarding dose interval, with a potential lower bioavalability in once daily regimens. The aim of this study is to assess the acute effects of carvedilol posology in patients with clinically significant portal hypertension (CSPH), as a surrogate marker of bioavailability. In this experimental study, patients with CSPH receiving carvedilol twice daily were asked to supress the night dose of carvedilol, in order to have a dose interval of approximately 24 hours. Spleen stiffness measurement (SSM) by transient elastography (TE) was performed and compared with SSM prior or under treatment. Same procedure was applied to liver stiffness measurement (LSM).

Conditions

• Clinically Significant Portal Hypertension

Interventions

Type	Name	Description
DRUG	supress the night dose of carvedilol	already described

Timeline

• Start date: 2023-06-01
• Primary completion: 2023-06-30
• Completion: 2023-07-31
• First posted: 2023-08-29
• Last updated: 2023-08-29

Locations

1 site across 1 country: Portugal